Roger Song
Stock Analyst at Jefferies
(4.30)
# 368
Out of 5,182 analysts
55
Total ratings
47.92%
Success rate
21.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTMX CytomX Therapeutics | Maintains: Buy | $8 → $16 | $4.25 | +276.47% | 4 | Mar 18, 2026 | |
| MANE Veradermics | Initiates: Buy | $75 | $58.04 | +29.22% | 1 | Mar 2, 2026 | |
| BIOA BioAge Labs | Upgrades: Buy | $9 → $62 | $18.04 | +243.68% | 3 | Feb 18, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $310 → $371 | $264.22 | +40.41% | 2 | Feb 17, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $95 → $118 | $102.09 | +15.58% | 1 | Feb 2, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $13 → $42 | $14.88 | +182.26% | 3 | Jan 22, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $75.08 | +61.16% | 12 | Nov 26, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $62.01 | -27.43% | 1 | Nov 13, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $7.09 | +125.67% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $581.69 | -3.04% | 1 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.76 | +184.09% | 1 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $17 | $0.80 | +2,025.53% | 2 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $36 | $31.66 | +13.71% | 1 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $54 | $47.03 | +14.82% | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $6 | $5.89 | +1.95% | 2 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.43 | +319.58% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.21 | +118.07% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $7.10 | +266.20% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $8.79 | +218.54% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $3.95 | +77.22% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $66.27 | +34.30% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $8.42 | +196.91% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $15.60 | +162.82% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $20.86 | +67.79% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $60.10 | +114.64% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $105.04 | -7.65% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $33.67 | +226.70% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $3.37 | +938.58% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $4.22 | +113.27% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $27.05 | +676.34% | 1 | Sep 2, 2020 |
CytomX Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $8 → $16
Current: $4.25
Upside: +276.47%
Veradermics
Mar 2, 2026
Initiates: Buy
Price Target: $75
Current: $58.04
Upside: +29.22%
BioAge Labs
Feb 18, 2026
Upgrades: Buy
Price Target: $9 → $62
Current: $18.04
Upside: +243.68%
Krystal Biotech
Feb 17, 2026
Maintains: Buy
Price Target: $310 → $371
Current: $264.22
Upside: +40.41%
Protagonist Therapeutics
Feb 2, 2026
Maintains: Buy
Price Target: $95 → $118
Current: $102.09
Upside: +15.58%
Corvus Pharmaceuticals
Jan 22, 2026
Maintains: Buy
Price Target: $13 → $42
Current: $14.88
Upside: +182.26%
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $75.08
Upside: +61.16%
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $62.01
Upside: -27.43%
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $7.09
Upside: +125.67%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $581.69
Upside: -3.04%
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.76
Upside: +184.09%
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.80
Upside: +2,025.53%
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $31.66
Upside: +13.71%
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $47.03
Upside: +14.82%
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $5.89
Upside: +1.95%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.43
Upside: +319.58%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $3.21
Upside: +118.07%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $7.10
Upside: +266.20%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $8.79
Upside: +218.54%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $3.95
Upside: +77.22%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $66.27
Upside: +34.30%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $8.42
Upside: +196.91%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $15.60
Upside: +162.82%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $20.86
Upside: +67.79%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $60.10
Upside: +114.64%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $105.04
Upside: -7.65%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $33.67
Upside: +226.70%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $3.37
Upside: +938.58%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $4.22
Upside: +113.27%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $27.05
Upside: +676.34%